CPG
VYNE icon

Cornerstone Planning Group’s VYNE Therapeutics VYNE Stock Holding History

Cornerstone Planning Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$6 – 1347
2024
Q1 		$6 Buy
+2
New +$4 ﹤0.01% 1091

Other funds holding VYNE

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $100M AUM

Cornerstone Planning Group's VYNE Position: Q2 2024 in Review

Cornerstone Planning Group sold out of VYNE Therapeutics (VYNE) in Q2 2024, closing a stake of 2 shares — an estimated $6 sold.

Cornerstone Planning Group first reported a position in VYNE in Q1 2024 and held it in 1 quarter. The position peaked at $6 in Q1 2024. 32 funds tracked by Wall St. Rank hold VYNE as of Q2 2024.

  • Cornerstone Planning Group reported no remaining VYNE Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cornerstone Planning Group sold 2 VYNE Therapeutics shares in Q2 2024, an estimated $6.
  • Cornerstone Planning Group first reported a position in VYNE Therapeutics in Q1 2024 and held it in 1 quarter.
  • Cornerstone Planning Group's VYNE Therapeutics position peaked at $6 in Q1 2024.
  • 32 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2024.

Based on Cornerstone Planning Group's 13F filing for Q2 2024, filed 13 Aug 2024.